Skip to main content

Petros Pharmaceuticals, Inc.

PTPI
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001815903

No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Petros Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Petros Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Petros Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Walker Wayne RemellDirector881,333Jun 8, 20262
Silverman JoshuaDirector8,790,450Jun 5, 20262
Bernstein BruceDirector3,762,334Jun 5, 20262
Boctor FadySee Remarks894,986Jun 5, 20262
Arnold MitchellSee Remarks150,000Feb 21, 20250
Bradley GregDirector8,314Dec 26, 20230
Shulman John DDirector, 10% Owner5,703,544IndirectJan 3, 20220
JCP III SM Aiv, L.P.10% Owner5,703,544IndirectJan 3, 20220
Juggernaut Partners III GP, L.P.10% Owner5,703,544IndirectJan 3, 20220
Juggernaut Partners III GP, Ltd.10% Owner5,703,544IndirectJan 3, 20220
METP Holdings LLC10% Owner5,703,544IndirectJan 3, 20220
Metuchen Therapeutics, LLC10% Owner–Oct 20, 20210
Gesek AndrewPresident, Timm Medical–Aug 5, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 3, 2022 (view filing)6:13 AM ETDec 22, 202112 daysLateShulman John D and 4 othersDirector, 10% OwnerPPurchaseCommon Stock, par value $0.0001 per share+145.8K$3.43+$500.0K+2.6%5.70M after
Jan 3, 2022 (view filing)6:13 AM ETDec 22, 202112 daysLateShulman John D and 4 othersDirector, 10% OwnerPPurchase+109.3K$0.00$0–109.3K afterDerivative
Nov 30, 2021 (view filing)2:49 PM ETNov 291 dayShulman John D and 4 othersDirector, 10% OwnerPPurchaseCommon Stock, par value $0.0001 per share+500.0K$3.00+$1.50M+9.9%5.56M after
Nov 30, 2021 (view filing)2:49 PM ETNov 291 dayShulman John D and 4 othersDirector, 10% OwnerPPurchase+375.0K$0.00$0–375.0K afterDerivative
Oct 21, 2021 (view filing)8:47 AM ETOct 183 daysLateShulman John D and 4 othersDirector, 10% OwnerPPurchaseCommon Stock, par value $0.0001 per share+1.66M$1.72+$2.85M+48.9%5.06M after
Oct 21, 2021 (view filing)8:47 AM ETOct 183 daysLateShulman John D and 4 othersDirector, 10% OwnerPPurchase+1.66M$0.00$0–1.66M afterDerivative